$AGIO
Agios Pharmaceuticals Inc Stock $agio

$agio Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000143922223000119 Filed on August 03, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$7.399M	$6.712M
YoY Change	110.44%	20.24%
Cost Of Revenue	$633.0K	$1.108M
YoY Change	22.44%	154.71%
Gross Profit	$6.766M	$5.604M
YoY Change	125.61%	8.88%
Gross Profit Margin	91.44%	83.49%
Selling, General & Admin	$25.82M	$30.41M
YoY Change	-11.33%	7.59%
% of Gross Profit	381.64%	542.63%
Research & Development	$81.84M	$68.90M
YoY Change	25.98%	-7.55%
% of Gross Profit	1209.59%	1229.39%
Depreciation & Amortization	$1.600M	$1.807M
YoY Change	-19.23%	-21.13%
% of Gross Profit	23.65%	32.24%
Operating Expenses	$107.7M	$99.30M
YoY Change	65.72%	33.25%
Operating Profit	-$100.9M	-$93.70M
YoY Change	10.77%	-4.04%
Interest Expense	$8.375M	$8.254M
YoY Change	119.36%	360.35%
% of Operating Profit
Other Income/Expense, Net	$1.198M	$1.640M
YoY Change	10.72%	22.66%
Pretax Income	-$91.32M	-$83.81M
YoY Change	11.71%	-8.71%
Income Tax
% Of Pretax Income
Net Earnings	-$91.32M	-$83.81M
YoY Change	11.72%	-8.71%
Net Earnings / Revenue	-1234.27%	-1248.6%
Basic Earnings Per Share	-$1.64	-$1.51
Diluted Earnings Per Share	-$1.64	-$1.51
COMMON SHARES
Basic Shares Outstanding	55.74M shares	55.58M shares
Diluted Shares Outstanding	55.80M shares	55.60M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$647.5M	$702.6M
YoY Change	-11.02%	-14.25%
Cash & Equivalents	$64.33M	$84.75M
Short-Term Investments	$583.2M	$617.8M
Other Short-Term Assets	$38.40M	$36.75M
YoY Change	-17.4%	-13.19%
Inventory	$17.27M	$15.67M
Prepaid Expenses
Receivables	$1.200M	$2.251M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$704.4M	$757.2M
YoY Change	-10.27%	-12.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$16.79M	$79.50M
YoY Change	-34.02%	190.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$224.9M	$244.4M
YoY Change	-24.62%	-12.99%
Other Assets	$4.057M	$4.057M
YoY Change	3.95%	2.58%
Total Long-Term Assets	$302.9M	$327.9M
YoY Change	-23.39%	-14.26%
TOTAL ASSETS
Total Short-Term Assets	$704.4M	$757.2M
Total Long-Term Assets	$302.9M	$327.9M
Total Assets	$1.007B	$1.085B
YoY Change	-14.66%	-13.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.27M	$11.63M
YoY Change	27.42%	49.24%
Accrued Expenses	$30.49M	$43.52M
YoY Change	2.47%	53.31%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$58.43M	$55.14M
YoY Change	9.01%	13.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$1.156M	$65.78M
YoY Change	9.57%	6134.69%
Total Long-Term Liabilities	$1.156M	$65.78M
YoY Change	9.57%	6134.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$58.43M	$55.14M
Total Long-Term Liabilities	$1.156M	$65.78M
Total Liabilities	$120.4M	$120.9M
YoY Change	-7.48%	-5.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$726.7M	-$635.4M
YoY Change	43.31%	49.38%
Common Stock	$2.422B	$2.411B
YoY Change	1.98%	2.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$802.5M	$802.5M
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$886.8M	$964.2M
YoY Change
Total Liabilities & Shareholders Equity	$1.007B	$1.085B
YoY Change	-14.66%	-13.36%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$91.32M	-$83.81M
YoY Change	11.72%	-8.71%
Depreciation, Depletion And Amortization	$1.600M	$1.807M
YoY Change	-19.23%	-21.13%
Cash From Operating Activities	-$61.70M	-$66.75M
YoY Change	-13.53%	-10.08%
INVESTING ACTIVITIES
Capital Expenditures	$400.0K	-$3.000K
YoY Change	-1152.63%	-99.84%
Acquisitions
YoY Change
Other Investing Activities	$39.70M	$47.12M
YoY Change	-61.87%	-44.39%
Cash From Investing Activities	$39.40M	$47.13M
YoY Change	-62.14%	-43.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.900M	237.0K
YoY Change	60.07%	-453.73%
NET CHANGE
Cash From Operating Activities	-61.70M	-66.75M
Cash From Investing Activities	39.40M	47.13M
Cash From Financing Activities	1.900M	237.0K
Net Change In Cash	-20.40M	-19.39M
YoY Change	-160.17%	-327.62%
FREE CASH FLOW
Cash From Operating Activities	-$61.70M	-$66.75M
Capital Expenditures	$400.0K	-$3.000K
Free Cash Flow	-$62.10M	-$66.75M
YoY Change	-12.92%	-7.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Investment Income Net InvestmentIncomeNet	8254000	usd
CY2022Q2	us-gaap	Investment Income Net InvestmentIncomeNet	1793000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	16345000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	2487000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.97
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.97
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55604330	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55604330	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54799680	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54799680	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55435796	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55435796	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1291975000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	-6547000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1289000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15510000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-94774000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-186580000	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	3597000	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	4769000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	21876000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	26675000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	5738000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1382000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	150000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-10000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	5263000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4919000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	45000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1598000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7179000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4060000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1674000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2103000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3556000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6837000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7243000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1161000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3584000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6713000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-5551000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-2123000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	779000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-161931000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-171964000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	232486000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	607747000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	337453000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	668717000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	396000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4730000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	150000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	104721000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	56240000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	164000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2704000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1305000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2704000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1141000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-54506000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-114583000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139259000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	203126000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84753000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88543000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	11000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	801000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1842000	usd
CY2022	agio	Gain Loss On Sale Of Contingent Payments GainLossOnSaleOfContingentPayments	127900000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the recent COVID-19 pandemic, or other pandemics or public health emergencies, may in the future directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain. We have made estimates of the impact of the recent COVID-19 pandemic within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div>
CY2023Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	946900000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P5Y
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	871040000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	15000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8885000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	862170000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	970269000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	99000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	12634000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	957734000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	243	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	842200000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	0	security
CY2023Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	470000	usd
CY2023Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	14236000	usd
CY2023Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	965000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	15671000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	3806000	usd
CY2023Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	4544000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.057
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	7587000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	18660000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	19507000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	20151000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	20755000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3479000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	90139000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11193000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	78946000	usd
	us-gaap	Sublease Income SubleaseIncome	1700000	usd
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	2491000	usd
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	5078000	usd
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	1310000	usd
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	8879000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10884000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18105000	usd
CY2023Q2	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	14656000	usd
CY2022Q4	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	8425000	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2029000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2435000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1620000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1385000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	29189000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30350000	usd
CY2022Q4	agio	Contract With Customer Contractual Adjustment Reserve ContractWithCustomerContractualAdjustmentReserve	65000	usd
CY2022Q4	agio	Contract With Customer Rebate Reserve ContractWithCustomerRebateReserve	573000	usd
CY2022Q4	agio	Contract With Customer Right To Recover Product Reserve ContractWithCustomerRightToRecoverProductReserve	133000	usd
CY2022Q4	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	771000	usd
	agio	Current Year Provision For Contractual Adjustments CurrentYearProvisionForContractualAdjustments	631000	usd
	agio	Current Year Provisions For Rebate Reserve CurrentYearProvisionsForRebateReserve	1065000	usd
	agio	Provision For Right To Recover Product In Current Year ProvisionForRightToRecoverProductInCurrentYear	2064000	usd
	agio	Contract With Customer Current Year Reserve Provisions ContractWithCustomerCurrentYearReserveProvisions	3760000	usd
	agio	Prior Year Provision For Contractual Adjustments PriorYearProvisionForContractualAdjustments	0	usd
	agio	Prior Year Provisions For Rebate Reserve PriorYearProvisionsForRebateReserve	-7000	usd
	agio	Provision For Right To Recover Product In Prior Years ProvisionForRightToRecoverProductInPriorYears	0	usd
	agio	Contract With Customer Prior Years Reserve Provisions ContractWithCustomerPriorYearsReserveProvisions	-7000	usd
	agio	Contract With Customer Contract Adjustment Recoveries Current Year ContractWithCustomerContractAdjustmentRecoveriesCurrentYear	479000	usd
	agio	Contract With Customer Rebate Reserve Recoveries In Current Year ContractWithCustomerRebateReserveRecoveriesInCurrentYear	325000	usd
	agio	Contract With Customer Right To Recover Product Current Year Recoveries ContractWithCustomerRightToRecoverProductCurrentYearRecoveries	1958000	usd
	agio	Contract With Customer Current Year Reserve Recoveries ContractWithCustomerCurrentYearReserveRecoveries	2762000	usd
	agio	Contract With Customer Contract Adjustment Recoveries Prior Year ContractWithCustomerContractAdjustmentRecoveriesPriorYear	49000	usd
	agio	Contract With Customer Rebate Reserve Recoveries In Prior Years ContractWithCustomerRebateReserveRecoveriesInPriorYears	306000	usd
	agio	Contract With Customer Right To Recover Product Prior Year Recoveries ContractWithCustomerRightToRecoverProductPriorYearRecoveries	48000	usd
	agio	Contract With Customer Prior Years Reserve Recoveries ContractWithCustomerPriorYearsReserveRecoveries	403000	usd
CY2023Q2	agio	Contract With Customer Contractual Adjustment Reserve ContractWithCustomerContractualAdjustmentReserve	168000	usd
CY2023Q2	agio	Contract With Customer Rebate Reserve ContractWithCustomerRebateReserve	1000000	usd
CY2023Q2	agio	Contract With Customer Right To Recover Product Reserve ContractWithCustomerRightToRecoverProductReserve	191000	usd
CY2023Q2	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	1359000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	162000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	60000	usd
CY2023Q2	agio	Contract With Customer Allowance And Reserves Liability ContractWithCustomerAllowanceAndReservesLiability	1197000	usd
CY2022Q4	agio	Contract With Customer Allowance And Reserves Liability ContractWithCustomerAllowanceAndReservesLiability	711000	usd
CY2023Q2	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	1359000	usd
CY2022Q4	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	771000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	2206000	usd
	agio	Contract With Customer Asset Revenue Recognized ContractWithCustomerAssetRevenueRecognized	16074000	usd
	agio	Contract With Customer Asset Proceeds From Collection Of Receivables ContractWithCustomerAssetProceedsFromCollectionOfReceivables	16029000	usd
CY2023Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	2251000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5772564	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	48.81
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	853686	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	25.84
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	152849	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	9.97
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	684129	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	56.55
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21876000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26675000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21876000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26675000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7255433	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7255433	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6675246	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6675246	shares
CY2023Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001439222-23-000119-index-headers.html	Edgar Link	pending
0001439222-23-000119-index.html	Edgar Link	pending
0001439222-23-000119.txt	Edgar Link	pending
0001439222-23-000119-xbrl.zip	Edgar Link	pending
agio-20230630.htm	Edgar Link	pending
agio-20230630.xsd	Edgar Link	pending
exhibit102.htm	Edgar Link	pending
exhibit103.htm	Edgar Link	pending
exhibit104.htm	Edgar Link	pending
exhibit31-1x06x30x23.htm	Edgar Link	pending
exhibit31-2x06x30x23.htm	Edgar Link	pending
exhibit32-1x06x30x23.htm	Edgar Link	pending
exhibit32-2x06x30x23.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
agio-20230630_def.xml	Edgar Link	unprocessable
agio-20230630_lab.xml	Edgar Link	unprocessable
agio-20230630_pre.xml	Edgar Link	unprocessable
agio-20230630_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
agio-20230630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AGIO
Agios Pharmaceuticals Inc Stock $agio

2023 Q3 Form 10-Q Financial Statement

#000143922223000119 Filed on August 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO Agios Pharmaceuticals Inc Stock $agio

2023 Q3 Form 10-Q Financial Statement

#000143922223000119 Filed on August 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO
Agios Pharmaceuticals Inc Stock $agio